# A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

Source: https://onco.cc/trials/nct06533644/  
OnCo record `nct06533644` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Partial Oncolysis in prostate cancer, run by Syncromune, Inc., now recruiting.

## Summary

A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer is a phase 2 interventional study registered as NCT06533644 by Syncromune, Inc., with 91 participants planned, started 2025-05-29 and due to reach its primary completion in 2028-04-14. Interventions recorded: Partial Oncolysis and SV-102.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06533644
- Phase: 2
- Setting: A Phase 2a Multicenter, Dose-Escalation and Dose Optimization Study of SYNC-T Therapy SV-102 for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Sponsor: Syncromune, Inc.
- Enrolled: 91

## Sources

- ClinicalTrials.gov NCT06533644: https://clinicaltrials.gov/study/NCT06533644

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)

---
JSON: https://onco.cc/api/v1/entities/nct06533644.json